News
Novo Nordisk, GoodRX, CVS
Digest more
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...
In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...
What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.
Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...
The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback